Alterity Therapeutics Limited (ATHE) — Analyst outlook / Analyst consensus target is. Based on 8 analyst ratings, the consensus is bullish — 4 Buy, 4 Hold.
Analysts estimate Earnings Per Share (EPS) of $-2.98 and revenue of $0.00B for the next fiscal year.
Earnings Per Share (EPS) track record: 2024: actual $-3.12 vs est $-2.98 (missed -4.9%). 2025: actual $-1.14 vs est $-1.51 (beat +24.3%). Analyst accuracy: 82%.
ATHE Analyst Ratings
Buy
Based on 8 analysts giving stock ratings to Alterity Therapeutics Limited in the past 3 months
EPS Estimates — ATHE
82%
Analyst Accuracy
Accurate
2 years compared
Actual vs Estimate
2024
Actual –$3.12
vs Est –$2.98
▼ 4.6% off
2025
Actual –$1.14
vs Est –$1.51
▲ 32.1% off
Profitability Outlook
Company has been making losses in all recent fiscal years. EPS is improving but still negative. Analysts expect losses to continue near-term.
Revenue Estimates — ATHE
62%
Analyst Accuracy
Fair
2 years compared
Actual vs Estimate
2024
Actual $0.004B
vs Est $0.004B
▲ 3.8% off
2025
Actual $0.005B
vs Est $0.009B
▼ 71.7% off
Revenue Trend
Moderate revenue growth trend. Analysts forecast revenue contraction ahead.
